Role of PDGF in Cervical Cancer and Effects of Imatinib
Author Information
Author(s): Taja-Chayeb Lucia, Chavez-Blanco Alma, Martínez-Tlahuel Jorge, González-Fierro Aurora, Candelaria Myrna, Chanona-Vilchis Jose, Robles Elizabeth, Dueñas-Gonzalez Alfonso
Primary Institution: Instituto Nacional de Cancerología, Mexico
Hypothesis
Does targeting the PDGF pathway with imatinib mesylate inhibit the growth of cervical cancer cells?
Conclusion
The PDGFR system is frequently expressed in cervical cancer, and imatinib can inhibit the growth of cervical cancer cells.
Supporting Evidence
- PDGF receptors are frequently expressed in cervical cancer.
- Imatinib inhibits the growth of cervical cancer cells.
- High interstitial fluid pressure in tumors correlates with poor outcomes.
Takeaway
This study found that a protein called PDGF is often present in cervical cancer, and a drug called imatinib can help stop the cancer cells from growing.
Methodology
The study analyzed PDGF family member expression in cervical cancer cell lines and primary tumors, and tested the effects of imatinib on cell growth.
Limitations
The study was limited to a small number of cervical cancer cell lines and primary tumors.
Participant Demographics
Mean age of patients was 40.8 years; included various stages of cervical cancer.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website